studies
Otitis Treatment With OtoSight™ - Modification of Antibiotic Treatment Intervention in Children (OTO-MATIC)
Sponsored by PhotoniCare Inc.
The OTO-MATIC study is designed to assess the benefit of a medical imaging device, called OtoSight, that directly looks at the middle ear space, a part of the ear where ear infections develop. This study hopes to assist doctors to better see the middle ear and thereby determine the best treatment for patients experiencing middle ear problems.
This study is closed to enrollment and no longer accepting new participants.
Real World Community-Based HIV Rapid Start Antiretroviral with BFTAF versus Conventional HIV Antiretrovial Therapy start - The RoCHaCHa Study, A pilot study.
Investigator initiated collaboration with Gilead Sciences
The RoCHaCHa study evaluates Rapid Start Antiretrovirals (RSA), the process of starting antiretrovirals as quickly as possible after a reactive HIV test. Using a single tablet regimen of Biktarvy, the study aims to determine if this RSA is an effective regimen for achieving vial suppression. This study concluded that RSA is feasible and well accepted by patients in a real-world community-based clinic setting as a tool in ending the HIV epidemic.
IDWeek 2020 POSTER IDWeek 2021 POSTER FINAL PAPER PUBLICATION
Observational Cohort Study of Cabenuva Utilization, Outcomes, and Patient Experience in the United States (BEYOND).
Sponsored by ViiV Healthcare
The BEYOND study helps better understand experiences of people using Cabenuva (a long-acting injectable treatment option for people living with HIV). The information collected will provide participants’ reasons for switching from oral medication to an injectable form of treatment, medical history, and overall experience and satisfaction with Cabenuva. Patients who switched to Cabenuva reported a strong preference for it over oral medications, increased treatment satisfaction, and more opportunities to engage with their HIV care. This study is closed to enrollment and no longer accepting participants.
Perspectives of People with HIV (PWH) 6 Months Following a Switch to Cabotegravir and Rilpivirine Long-acting (CAB+RPV LA) in an Observational Real-world US Study (BEYOND)
Perspectives of people with HIV (PWH) 12 months following a switch to cabotegravir and rilpivirine long-acting (CAB+RPV LA) in an observational real-world US study (BEYOND)
A Phase 4, Randomized, Open-label, Two-arm Study Evaluating Implementation Strategies for the Delivery of Cabotegravir in Low and High-volume Pre-exposure Prophylaxis (PrEP) Sites in the U.S. for HIV Uninfected MSM and Transgender Men ≥ 18 (PILLAR).
Sponsored by ViiV Healthcare
The PILLAR study evaluates the integration of Apretude (long-acting injectable Cabotegravir) for PrEP care as a form of prevention against HIV. The focus is on men who have sex with men (MSM) and transgender men on Apretude and the medical staff who provide it. Outcomes of clinic implementation strategies will be considered while learning about patient barriers to care, reasons for switching to an injectable form of treatment, and habits around continuing or stopping PrEP.
A Study Evaluating Implementation Strategies for the Delivery of Cabotegravir in Low and High-Volume PrEP Site in the United States (PILLAR)
Integrating Long-acting Injectable Cabotegravir for PrEP into Standard of Care for Cisgender Women, Transgender Women, Transgender Men, and Men Who Have Sex with Men: Results from the PILLAR & EBONI Studies
publications
Willingness to Take PrEP for HIV Prevention: The Combined Effects of Race/Ethnicity and Provider Trust
Amy Braksmajer, Theresa M. Fedor, Shaw-Ree Chen, Roberto Corales, Sally Holt, William Valenti, James M. McMahon